The role of DKK1 in hepatocellular carcinoma treated with sorafenib
碩士 === 國立臺灣大學 === 醫學檢驗暨生物技術學研究所 === 102 === Sorafenib is a drug for standard systemic therapy in patients with advanced hepatocellular carcinoma (HCC), and it is also the first drug with survival benefits. Although Sorafenib was originally designed as a specific Raf kinase inhibitor, we and other in...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2014
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/05759363279221001808 |